Journal of Clinical Oncology
Articles in this Issue
Depth of response and progression-free survival in patients with advanced <i>ALK</i> -positive non–small-cell lung cancer treated with lorlatinib.
8589 Background: After 5 years of follow-up in patients with ALK -positive non-small cell lung cancer (NSCLC) treated with lorlati...
Trends in colorectal cancer and iron deficiency anemia–related mortality in the United States: A nationwide retrospective analysis over 24 years.
e15648 Background: Iron deficiency anemia (IDA) is the most common extra intestinal symptom in patients with colorectal cancer (CRC). IDA is also linked t...
Development of an early sepsis treatment-decision algorithm in children and adolescents with cancer in a middle-income country: Results from a multinational modified Delphi consensus.
1540 Background: Despite global efforts, striking childhood cancer survival gaps between low- and middle-income countries (LMIC) and high-income countries...
Cancer–heart cross talk: Cytokine release pattern from anthracycline-treated cancer cell lines and their impact on cardiomyocyte metabolism.
e24015 Background: Anthracyclines are effective cancer therapeutics but can cause cardiotoxicity. Recent studies suggest a connection between efficacy and...
Pathognomonic genetic signatures of gallbladder cancer: Results of ongoing prospective study.
e16236 Background: Gene polymorphisms play a pivotal role in gallbladder cancer (GBC) susceptibility and progression, underscoring the need to pinpoint ke...
Outcomes associated with distress thermometer (DT) screening among patients with cancer: A retrospective, observational study in the US community oncology setting.
e23295 Background: The DT is widely used to screen patients, especially those with cancer, for psychological distress and health-related social needs. DT-...
Investigation of the quality of life of cervical cancer patients and analysis of clinical data based on the CC-PRO137 scale.
e17523 Background: Cervical cancer is the most prevalent malignant neoplasm of the female reproductive system. China accounts for close to 1/5 of the worl...
Analytical validation of a 1021-gene NGS panel for comprehensive tumor profiling in FFPE and liquid biopsy samples.
e14629 Background: In the era of targeted therapy and immunotherapy, accurate molecular profiling through next-generation sequencing (NGS) is essential fo...
Final results of POD1UM-201, a phase 2 study of retifanlimab, a humanized anti–PD-1 antibody, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
9536 Background: Retifanlimab is approved in the United States and Europe for treatment of adults with metastatic or recurrent locally advanced MCC, based...
A multicenter randomized phase II study of trastuzumab biosimilar (CT-P6) and chemotherapy (SOX or CapeOX) in HER2-positive advanced/recurrent gastric cancer (KSCC: TROX study).
4029 Background: The efficacy and safety of the trastuzumab biosimilar (CT-P6) combined with S-1/oxaliplatin (SOX) or capecitabine/oxaliplatin (CapeOX) we...
Use of artificial intelligence to identify high risk profiles in early stage melanoma patients from pathology slides.
9579 Background: To refine prognostication in primary cutaneous melanoma (CM) and optimize adjuvant treatment decisions, we evaluate SmartProg-MEL (SPM),...
An NCDB study examining disparities in the administration of immunotherapy among advanced cervical cancer patients.
5524 Background: The addition of immunotherapy (IO) to standard therapy has demonstrated substantial survival benefits in the upfront treatment of advance...
Anemia as a predictive factor for brain metastases: A propensity score matched retrospective cohort study.
e14014 Background: Renal cell carcinoma, lung carcinoma, breast carcinoma, and melanoma are cancers that commonly metastasize to the brain. Currently, it...
A single-center, prospective, randomized controlled trial of tislelizumab combined with platinum-containing chemotherapy as first-line treatment for HIV-positive patients with advanced non-small cell lung cancer.
e20590 Background: There are few prospective clinical studies of programmed death-1 (PD-1) inhibitors combined with chemotherapy in the treatment of human...
TLR9 agonists as a potential therapeutic option for B-ALL patients with low P53 expression.
6526 Background: B-cell acute lymphoblastic leukemia (B-ALL) is a highly malignant hematologic cancer with poor prognosis, especially in relapsed or refra...
[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
3005 Background: [ 212 Pb]VMT-α-NET, a next generation 212 Pb-based, SSTR2-targeted alpha-particle radioph...
Predictive modeling by tumor type: Comparing performance and feature importance of machine learning–based predictive models in patients with hematologic and solid tumors.
e13638 Background: Oncology practices increasingly rely on vast datasets from electronic health records and patient-reported outcomes (PROs). Prior work h...
T-cell effector cytokine signature as predictor of survival and toxicity in metastatic NSCLC patients treated with immunotherapy.
8555 Background: Immune checkpoint inhibitors (ICIs) have led to significant prolongation of survival in patients with advanced non-small cell lung cancer...
Application of N-terminal telopeptide of type I collagen in the evaluation of bone metastasis degree and efficacy.
e23505 Background: Bone metastases is a common complication in advanced malignancies, and the assessment of their severity and treatment response currentl...
Feasibility trial of health coaching-based navigation after breast cancer treatment.
1637 Background: Following breast cancer diagnosis, 25% of survivors experience psychosocial needs like depression, anxiety, and fear of recurrence. Integ...
Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.
TPS1139 Background: Patients (pts) with hormone receptor (HR)-negative and HER2-low-expressing (defined as IHC 1+, or IHC 2+/ISH-) advanced breast cancer...
Exosomal proteins as biomarkers for differential diagnosis of pleural effusion etiologies.
e20508 Background: The clinical need for differential diagnosis of pleural effusion etiologies remains unmet. This study aimed to identify exosomal protei...
Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
6574 Background: BET proteins are epigenetic readers that regulate expression of oncoproteins involved in hematologic malignancies, including MF. The oral...
Olink proteomics analysis to identify biomarkers of radiation- and immunotherapy-induced pneumonitis.
e20604 Background: Lung cancer remained one of the cancers with the highest incidence and mortality globally. Although the combination of radiation therap...
Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma.
7004 Background: Although Bispecific Antibodies (BsAbs) have the advantage of an “off the shelf” immune approach, their clinical activity relies on the pa...